Background Human papillomavirus (HPV) vaccination programmes were first implemented
in several countries worldwide in 2007. We did a systematic review and meta-analysis to …

Oncogenic human papillomavirus (HPV) infection is the cause of nearly all cervical cancers
and a proportion of other anogenital and oropharyngeal cancers. A bivalent vaccine …

Abstract Problem/Condition: Malaria in humans is caused by intraerythrocytic protozoa of the
genus Plasmodium. These parasites are transmitted by the bite of an infective female …

Background The long-term effectiveness of the quadrivalent human papillomavirus (qHPV)
vaccine was assessed by monitoring the combined incidence of cervical intraepithelial …

Background In clinical trials, vaccines against human papillomavirus (HPV) have been
highly effective against HPV16-or HPV18-associated cervical lesions. The quadrivalent HPV …

Background: A quadrivalent human papillomavirus (HPV4) type 6/11/16/18 vaccine
(GARDASIL/SILGARD®) has been licensed in many countries around the world for the …

We currently have the knowledge and experience to prevent much of human papillomavirus
(HPV)-related disease burden globally. In many countries where prophylactic HPV …

Human papillomavirus (HPV) vaccine uptake consistently lags behind that of other
adolescent vaccines. In 2017, uptake of a single HPV vaccine dose and HPV vaccine series …

Cervical cancer control includes primary prevention through vaccination to prevent human
papillomavirus (HPV) infection and secondary prevention through screening to detect and …

Background A reduced, 2-dose schedule of human papillomavirus (HPV) vaccination has
been endorsed for preadolescent women on the basis of immunogenicity data from …